Dosing Begins in 2nd Phase 3 Trial of Antibody Treatment for IPF

Dosing Begins in 2nd Phase 3 Trial of Antibody Treatment for IPF

282040

Dosing Begins in 2nd Phase 3 Trial of Antibody Treatment for IPF

Dosing has begun in a second Phase 3 trial testing FibroGen’s investigational antibody pamrevlumab in treating idiopathic pulmonary fibrosis (IPF). Still recruiting eligible patients at sites in three European countries — Georgia, Italy, and Hungary — and in Lebanon, the ZEPHYRUS-2 study (NCT04419558) is expected to enroll 340 people, ages 40 to 85, who were previously treated with approved IPF therapies — Esbriet (pirfenidone) or Ofev (nintedanib) — but had stopped using them. Contact and site information can…

You must be logged in to read/download the full post.